An interesting product currently being used by the Asian Diabetes Association, the Red Cross Hospital in Beijing and nearly 50 hospitals in China as a medical treatment for Type II Diabetes, is an herbal product called Yu Xiao San 8805.

Developed by Dr. Lianjin Chong, Director of The Red Cross Hospital in Beijing, it is designed to restore pancreatic function and to increase insulin beta cells.

This product has been clinically shown to gradually and effectively lower blood-sugar levels and increase insulin secretion. Additionally, it has also been shown to help regulate carbohydrate metabolism, improve blood circulation, lower blood cholesterol and increase immune response.

Yu Xiao San 8805 has undergone experimental tests in both the United States and China with good results, and has further been used by diabetics in over fifty countries worldwide. So far, no adverse or allergic reactions have been reported from its use, nor have there been any reports of damage to the liver, kidney or any other organs

From February to October 1992, 10,618 patients were chosen based on the diagnostic guidelines established for diabetes mellitus by the World Health Organization. These cases were selected for clinical assessment from the China Beijing Chao Yang District Red Cross Hospital and from 48 other similar hospitals across the nation.

Here are the results after 4 months of treatment and monitoring:

• 1794 (19.12%) patients with Type II diabetes were able to discontinue their diabetes medications;
• 2346 (25.01%) patients saw their diabetes symptoms significantly improve and diabetic complications reduced;
• 3835 (40.88%) noticed some improvement; and
• 1407 (15.00%) experienced no evidence of symptom improvement nor diabetes improvements.

The primary herb components of Yu Xiao San are being patented, to be sold in the United States as a health food.

Research published in the medical journal Lancet reveals that life-threatening diabetes is becoming an epidemic not only in North America, but in Asia as well. And it appears to be only getting worse.

According to doctors at the Catholic University of Korea in Seoul, 194 million Asians were diabetic in 2003, a statistic that could soar to 330 million by the year 2025.

The Lancet research suggests Asians are developing diabetes at a younger age and at lower weight; they suffer longer with complications; and the also die earlier than people in developed countries. This onset of adult diabetes in increasingly younger populations will negatively affect Asian countries economically, as a result of higher health costs and mortality rates.

And while nearly one million people die from diabetes-related heart disease and stroke each year worldwide, another study in the Lancet also reveals that pre-diabetic conditions can be equally deadly. A Harvard School of Public Health team has found that elevated blood sugar below the diabetes threshold kills more than two times as many people every year as diabetes does — specifically, 2.2 million people, with 84% of these living in developing countries.

“Of these 2.2 million, many of them are not called diabetics,” says researcher Majid Ezzati, who led the Harvard study. “They are people who could have benefited from lowering their blood glucose, but they are not at the threshold that we call disease.”

When the total annual deaths from high blood sugar, including diabetes, are tallied together, the sum is over three million. Ezzati puts this number into perspective, by comparing it to the nearly five million deaths each year related to smoking, and the four million due to high blood cholesterol.

According to the IDF’s 2003 statistics, the top 5 countries with the largest number of diabetics were:

1. India - 35.5 million
2. China - 23.8 million
3. USA - 16.0 million
4. Russia - 9.7 million
5. Japan - 6.7 million

Doctors and medical professionals who work with Asians are becoming alarmed by the dramatic rise in diabetes cases in that demographic group.

The World Health Organization and the International Diabetes Federation predict that the number of diabetics in Asia could increase to 160 million by the year 2025.

This rise in diabetes among Asians has prompted the Joslin Diabetes Center in Boston, working with the Harvard Medical School, begun an initiative called the Asian Diabetes Initiative. Through this, they hope to improve awareness and management of diabetes among Asian Americans.

A community collaborative of:

Harvard Tai Chi Tiger Crane Club

Mission

To fight diabetes and its complications in the local & global Asian communities

Goals & Objectives

• To prevent the widespread growth of diabetes through education & public awareness
• To find a cure for diabetes though the support of research